Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party - Sorbonne Université
Journal Articles Haematologica Year : 2021

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

Joerg Henes
  • Function : Author
Myriam Labopin
Nicoletta del Papa
  • Function : Author
Marc Schmalzing
  • Function : Author
Roland Schroers
  • Function : Author
David Michonneau
John Snowden
  • Function : Author
Montserrat Rovira
  • Function : Author
Lothar Kanz
  • Function : Author

Abstract

Three randomized controlled trials in early severe systemic sclerosis demonstrated that autologous hematopoietic stem cell transplantation was superior to standard cyclophosphamide therapy. This European Society for Blood and Marrow Transplantation multi-center prospective non-interventional study was designed to further decipher efficacy and safety of this procedure for severe systemic sclerosis patients in real-life practice and to search for prognostic factors. All consecutive adult systemic sclerosis patients undergoing a first autologous hematopoietic stem cell transplantation between December 2012 and February 2016 were prospectively included in the study. Primary endpoint was progression free survival. Secondary endpoints were overall survival, non-relapse mortality, response and incidence of progression. Eighty systemic sclerosis patients were included. Median follow-up duration was 24 (6-57) months after stem cell transplantation using cyclophosphamide plus antithymocyte globulins conditioning for all, with CD34+ selection in 35 patients. At 2 years, progression free survival was 81.8%, overall survival was 90%, response was 88.7% and incidence of progression was 11.9%. The 100 days non-relapse mortality was 6.25% (n=5) with four deaths from cardiac event, including three due to cyclophosphamide toxicity. Modified Rodnan skin score and forced vital capacity improved with time (p< 0.001). By multivariate analysis, baseline skin score >24 and older age at transplant were associated with lower progression free survival (Hazard ration 3.32) and 1.77, respectively). CD34+-selection was associated with better response (Hazard ration: 0.46). This study confirms the efficacy of autologous stem cell transplantation in real-life practice for severe systemic sclerosis using non myeloablative conditioning. Careful cardio-pulmonary assessment to identify organ involvement at patient referral, reduced cyclophosphamide doses and CD34+ selection may improve outcomes. The study was registered at ClinicalTrials.gov: NCT02516124.
Fichier principal
Vignette du fichier
9613-Article Text-71077-2-10-20210126.pdf (451.57 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03241950 , version 1 (29-05-2021)

Identifiers

Cite

Joerg Henes, Maria Carolina Oliveira, Myriam Labopin, Manuela Badoglio, Hans Ulrich Scherer, et al.. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica, 2021, 106 (2), pp.375-383. ⟨10.3324/haematol.2019.230128⟩. ⟨hal-03241950⟩
252 View
43 Download

Altmetric

Share

More